Clinical Trial Search

Primary: Number of Subjects With an Investigator Assessment of Clinical Outcome (Success/Failure) at End of Study — 275; 133 participants

Primary: Proportion of Patients Receiving Antibiotics or a Prescription for Antibiotics in the ED — 20; 33 Participants

Primary: Compliance (Was the Dosage Followed - Yes, no) — 3154; 12; 15; 2 Participants

Primary: Number of Subjects With Bacterial Aetiology, Assessed by Culture Growth, From Bronchoalveolar Lavage (BAL) Fluid Samples — 141; 49; 1; 58 Participants

Primary: Incidence Rates of First Episode of Respiratory Syncytial Virus (RSV) Respiratory Tract Infection (RTI) [Period 1] — 7.93 Cases per 100 person-years

Primary: Number of Patients With Adverse Events (AEs) — 27 participants

Primary: Body Temperature — 183; 170; 13; 2617 Participants

Primary: Antibiotic Sparing — 89; 121 Participants — p=0.025

Primary: Mean Estimated Number of Acute Exacerbation of COPD (AECOPD) — 3.04 AECOPD/subject/year

Primary: Health Related Quality of Life Score — 91.5; 90.2 scores on a scale — p=0.008

Primary: Satisfaction With Time to Receive Result — 180; 53; 3; 72 participants

Primary: Time for Viral Load to Drop Below Assay Quantification Limit (BQL) (Plaque Assay Analysis) — 46.1; 14.2; 5.1; 5.1 hours — p=<0.001

Primary: Lung Function — 0.071; -3.179; 0.186; -3.345 Z score — p=0.0020

Primary: Average Time From Baseline to Recovery From Cough and Other Symptoms — 7.06; 6.76; 7.82; 9.05 Days

Primary: Summary Scores on the SUM8 Daily Cough and Phlegm Diary Card On the Morning of Day 4 — 12.96; 12.87; 12.71 units on a scale

Primary: Incidence of Urinary Tract Infection — 7; 13 participants

Primary: Time-Weighted Average Change in Viral Load From Day 1/Baseline Through Day 7 in Participants in the Full Analysis Set — -0.73; -0.90 log10 copies/mL — p=0.72

Primary: Time to Hospital Discharge — 7.1; 7.5 Days — p=0.5634

Primary: Number of Participants With at Least One LRTI During Follow-up Period — 16; 20; 17; 138 Participants — p=0.68

Primary: Percentage of Patients With Clostridium Difficile Infection at 4- Weeks of Follow-up. — 2; 7 Participants — p=0.045

Primary: Average Time From Baseline to Recovery From Fever and Other Symptoms — 7.18; 7.14; 7.88 Days

Primary: Clinical Sensitivity and Specificity for Microorganism Detection as Compared to Routine Microbiology and Other Reference Methods Including PCR and Sequencing — 91.4…

Primary: Number of Participants With Clinical Failure (Failure to Reach Clinical Stability) — 6; 2 Participants — p=.460

Primary: Parental Anxiety — 4.2; 3.9 points on a scale

Primary: Mean Asthma Symptom Score — 2.3; 2.1 Asthma symptom score

Primary: Neutrophil Cell Counts in Tracheal Lavages — 112.02; 26.98; 61.72; 27.63 neutrophil/high powered field — p=<0.05

Primary: Prevalence of Respiratory Tract-Related Adverse Events of Interest — 52; 51; 16; 14 percentage of participants

Primary: Progression to Clinically Significant Lower Respiratory Tract Symptoms — 35; 57 participants — p=0.04

Primary: Time-weighted Average Change in Nasal Respiratory Syncytial Viral (RSV) Load From Baseline to Day 9 — -1.00; -0.97 log10 copies/mL — p=0.94

Primary: Number of Patients With Positive Culture or Molecular Results After Brochoscopy — 40 participants